Consultant in Medical Oncology
0161 918 7672
0161 918 8342
MB BChir PhD MRCP
Renal and oesophagogastric cancer and immunotherapy
Dr Thistlethwaite takes renal cancer referrals from Salford, Wigan and Bolton, and oesophagogastric cancer referrals from Salford and Wigan; She is a member of the Safe Medicines Practice Committee, the Drug and Therapeutics Committee and the Systemic Anti-Cancer Therapy delivery group.
Dr Thistlethwaite is an Honorary Senior Lecturer at The University of Manchester. She graduated from The University of Cambridge MB PhD programme in 1999. Her PhD, under the supervision of Professor Sir Martin Evans, explored the molecular mechanisms that lead to cancer in inherited breast cancer syndromes. Following training posts at Liverpool Royal, The Royal Marsden and The Christie, she became a consultant at The Christie in 2007.
Her clinical practice is in renal cancer and oesophagogastric cancer and her academic focus is clinical trial development in immunotherapy and adoptive T-cell therapy. Dr Thistlethwaite is a co-applicant on the ATTACK project (an EU Framework Programme Six (FP6) Integrated Project) and is the Chief Investigator for the ATTACK-OG trial within this project. The ATTACK-OG trial is a phase II trial of adoptive transfer of gene-modified T cells targeted towards the cancer antigen NYESO in oesophagogastric cancer.
She is a member of the National Cancer Research Institute Renal Clinical Studies Group. Dr Thistlethwaite recently completed the Manchester Academic Health Science Centre science for academics course. This will help her develop projects to improve service delivery.
Dr Thistlethwaite has an active clinical trials research portfolio in renal and oesophagogastric cancer and in immunotherapy. Her research focuses on how the immune system can be harnessed against cancer, in particular using adoptive cell transfer of T-cells activated against cancer antigens.